Oncogenic ALK <sup>F1174L</sup> drives tumorigenesis in cutaneous squamous cell carcinoma.

Détails

Ressource 1Télécharger: 32312912_BIB_3430322C06A8.pdf (3322.88 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_3430322C06A8
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Oncogenic ALK <sup>F1174L</sup> drives tumorigenesis in cutaneous squamous cell carcinoma.
Périodique
Life science alliance
Auteur⸱e⸱s
Gualandi M., Iorio M., Engeler O., Serra-Roma A., Gasparre G., Schulte J.H., Hohl D., Shakhova O.
ISSN
2575-1077 (Electronic)
ISSN-L
2575-1077
Statut éditorial
Publié
Date de publication
06/2020
Peer-reviewed
Oui
Volume
3
Numéro
6
Pages
e201900601
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Résumé
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer characterized by increased mortality. Here, we show for the first time that anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase of the insulin receptor superfamily, plays a pivotal role in the pathogenesis of cSCC. Our data demonstrate that the overexpression of the constitutively active, mutated ALK, ALK <sup>F1174L</sup> , is sufficient to initiate the development of cSCC and is 100% penetrant. Moreover, we show that cSCC development upon ALK <sup>F1174L</sup> overexpression is independent of the cell-of-origin. Molecularly, our data demonstrate that ALK <sup>F1174L</sup> cooperates with oncogenic Kras <sup>G12D</sup> and loss of p53, well-established events in the biology of cSCC. This cooperation results in a more aggressive cSCC type associated with a higher grade histological morphology. Finally, we demonstrate that Stat3 is a key downstream effector of ALK <sup>F1174L</sup> and likely plays a role in ALK <sup>F1174L</sup> -driven cSCC tumorigenesis. In sum, these findings reveal that ALK can exert its tumorigenic potential via cooperation with multiple pathways crucial in the pathogenesis of cSCC. Finally, we show that human cSCCs contain mutations in the ALK gene. Taken together, our data identify ALK as a new key player in the pathogenesis of cSCC, and this knowledge suggests that oncogenic ALK signaling can be a target for future clinical trials.
Mots-clé
Anaplastic Lymphoma Kinase/genetics, Anaplastic Lymphoma Kinase/metabolism, Animals, Carcinogenesis/genetics, Carcinogenesis/metabolism, Carcinoma, Squamous Cell/genetics, Carcinoma, Squamous Cell/metabolism, Disease Models, Animal, HEK293 Cells, Humans, Mice, Mice, Inbred C57BL, Mice, Transgenic, Mutation, Oncogenes, Signal Transduction/genetics, Skin Neoplasms/genetics, Skin Neoplasms/metabolism, Transfection
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/04/2020 18:51
Dernière modification de la notice
23/01/2024 8:23
Données d'usage